CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

218 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, single-center, non-randomized, non-controlled observational study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prediction of Axillary Lymph Node Metastasis Status in Breast Cancer Based on PET/CT Radiomics

NCT05826197

Breast Neoplasms

UNKNOWN

Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer

NCT03592004

Breast Cancer Radiomics Neoadjuvant Chemotherapy +1 more

UNKNOWN

MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)

NCT04004559

Invasive Breast Cancer Neoadjuvant Chemotherapy Radiomics +2 more

UNKNOWN

Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients

NCT04145947

Triple Negative Breast Cancer

UNKNOWN

Predict the Risk of Axillary Metastases in Breast Cancer Patients With Axillary Ultrasound

NCT02992769

Breast Cancer Female

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Almost 55-62% of patients with triple-negative or human epidermal growth factor receptor 2 (HER2) positive, node-positive breast cancer achieve an axillary pathologic complete remission (pCR) after neoadjuvant chemotherapy (NAC). To avoid surgery post-NAC, it is paramount to accurately identify patients who achieve pCR in axillary lymph node (ALN). We found that patients with normal-appearing lymph nodes on computed tomography (CT) based radiomics of the axilla after chemotherapy had a lower risk of developing residual nodal disease. However, the features of CT-based radiomics for pCR ALN following NAC has not been established yet. This study aimed to assess the performance of CT-based radiomics in evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast cancer patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Triple-negative Breast Cancer HER2-positive Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Triple-negative and HER2 Positive breast cancer

Patients with triple-negative or HER2 Positive breast cancer, axillary lymph node metastasis who underwent NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis. CT-based radiomics will be uesd in evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast cancer patients.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Triple-negative or HER2-positve invasive breast cancer with axillary lymph node metastasis by confirmed by fine needle aspiration or core needle biopsy.
* Underwent computed tomography for assessment of axillary lymph node status before and after neoadjuvant chemotherapy.
* Attend the study voluntarily, sign the informed consent.